These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers. Muir KW; Grosset DG; Lees KR Clin Neuropharmacol; 1997 Aug; 20(4):311-21. PubMed ID: 9260729 [TBL] [Abstract][Full Text] [Related]
10. The effect of non-competitive N-methyl-D-aspartate receptor antagonism on cerebral oedema and cerebral infarct size in the aging ischaemic brain. Davis M; Perry RH; Mendelow AD Acta Neurochir Suppl; 1997; 70():30-3. PubMed ID: 9416269 [TBL] [Abstract][Full Text] [Related]
11. The chemical biology of clinically tolerated NMDA receptor antagonists. Chen HS; Lipton SA J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772 [TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Dyker AG; Edwards KR; Fayad PB; Hormes JT; Lees KR Stroke; 1999 Oct; 30(10):2038-42. PubMed ID: 10512904 [TBL] [Abstract][Full Text] [Related]
13. Protective effects of aptiganel HCl (Cerestat) following controlled cortical impact injury in the rat. Kroppenstedt SN; Schneider GH; Thomale UW; Unterberg AW J Neurotrauma; 1998 Mar; 15(3):191-7. PubMed ID: 9528919 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers. Hu LY; Guo J; Magar SS; Fischer JB; Burke-Howie KJ; Durant GJ J Med Chem; 1997 Dec; 40(26):4281-9. PubMed ID: 9435897 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of action of neuroprotectants in stroke. Lyden P; Wahlgren NG J Stroke Cerebrovasc Dis; 2000 Nov; 9(6 Pt 2):9-14. PubMed ID: 17895214 [TBL] [Abstract][Full Text] [Related]